Berlin-based precision oncology startup developing AI-driven biomarker discovery and clinical decision tools. Its Polaris platform combines H&E histology with RNA-Seq to identify prognostic and predictive biomarkers; the first product, Polaris Breast, assesses metastasis risk in early breast cancer and is undergoing regulatory approval in the EU and US.
Investment Rounds
Capital activity and funding progression
| Amount | Date | Round |
|---|---|---|
| €12.5 M | Oct, 2025 | unspecified |
Frequently Asked Questions
What industries does StratifAI operate in?
StratifAI operates in the following industries: precision oncology, healthtech, medical diagnostics, biotech, artificial intelligence.
How much total funding has StratifAI raised?
StratifAI has raised a total of $12,500,000.
Who are the investors in StratifAI?
The investors in StratifAI are: Alven, Heliad, Rubin Ritter, Lars Langusch, Jens Begemann, Debiopharm, Arve Capital, Christoph Haarburger, Picus Capital.